Yasmine Mahmoud Massoud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yasmine Mahmoud Massoud has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Iman Fawzy Montasser
Department of Tropical Medicine, Ain Shams University, Cairo, Egypt
3 shared publications - Ahmed Marwan
Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
1 shared publication Amany Ahmad Ibrahim
Department of Tropical Medicine, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt
1 shared publicationAshraf Mahmoud El-Sayed
Tropical Medicine Department, Faculty of medicine, Ain Shams University
1 shared publication- Ayat Abdallah Abd-Elkalik
Tropical Medicine Department, Faculty of medicine, Ain Shams University
1 shared publication - Ayman Yosry
Endemic Medicine and Hepatogastroenterology, Cairo University, Cairo, Egypt
1 shared publication
Latest Publications
- Open Access
- 11 May 2026
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 16 (1) , 30
Conference recommendations on immunosuppression practice for adult liver transplantation in Egypt
Background: Adult living donor liver transplantation (LDLT) started in Egypt in 2001, with more than 5000 cases transplanted since then. In Egypt using only ABO compatible donor is the practice in all cases, and up till now, the only oncological indication for LDLT is hepatocellular carcinoma (HCC). The optimal management of the transplant recipient relies on understanding and proper utilization of immunosuppression regimens. The clinician should be aware of how to maintain the delicate balance between under-immunosuppression, leading to graft rejection, and over-immunosuppression, leading to the consequences of immunodeficiency such as sepsis and malignancy. The aim of this consensus is to provide clinical guidance to transplant physicians, transplant surgeons, clinical pharmacologists and nurses about immunosuppression in LDLT recipients. Main body: These national recommendations on immunosuppression in adult LDLT were developed by an experience exchange between the 22 centers currently undergoing LDLT in Egypt. A group of experts in liver transplantation from all over Egypt participated in the review of literature for different aspects related to these recommendations and, then they shared in formulation of several statements. In the United Conference on Hepato-gastroenterology and Infectious Diseases (UCHID) (2022), voting on these statements was done. Conclusion: Comprehensive national guidance is provided regarding the general principles of liver transplant immunosuppression, types of immunosuppression (IS), established IS drugs, types of rejection and their management, treatment of special groups, immunosuppression minimization, immune tolerance and complete IS withdrawal and the role of liver biopsy in orchestrating immunosuppression.
- 11 May 2026
- Published by Springer Nature in Egyptian Liver Journal
- Vol. 16 (1) , 30
Open AccessConference recommendations on immunosuppression practice for adult liver transplantation in Egypt
Background: Adult living donor liver transplantation (LDLT) started in Egypt in 2001, with more than 5000 cases transplanted since then. In Egypt using only ABO compatible donor is the practice in all cases, and up till now, the only oncological indication for LDLT is hepatocellular carcinoma (HCC). The optimal management of the transplant recipient relies on understanding and proper utilization of immunosuppression regimens. The clinician should be aware of how to maintain the delicate balance between under-immunosuppression, leading to graft rejection, and over-immunosuppression, leading to the consequences of immunodeficiency such as sepsis and malignancy. The aim of this consensus is to provide clinical guidance to transplant physicians, transplant surgeons, clinical pharmacologists and nurses about immunosuppression in LDLT recipients. Main body: These national recommendations on immunosuppression in adult LDLT were developed by an experience exchange between the 22 centers currently undergoing LDLT in Egypt. A group of experts in liver transplantation from all over Egypt participated in the review of literature for different aspects related to these recommendations and, then they shared in formulation of several statements. In the United Conference on Hepato-gastroenterology and Infectious Diseases (UCHID) (2022), voting on these statements was done. Conclusion: Comprehensive national guidance is provided regarding the general principles of liver transplant immunosuppression, types of immunosuppression (IS), established IS drugs, types of rejection and their management, treatment of special groups, immunosuppression minimization, immune tolerance and complete IS withdrawal and the role of liver biopsy in orchestrating immunosuppression.
- Open Access
- 1 August 2023
- Published by Egyptian Knowledge Bank in Journal of the Egyptian Society of Parasitology
- Vol. 53 (2) , 227-232
EVALUATION OF CLINICAL UTILITY OF DETECTING CIRCULATING TUMOR DNA MUTATION GENE LOCUS TP53 RS28934571 USING REAL TIME PCR AND DROPLET DIGITAL PCR IN EGYPTIAN HEPATOCELLULAR CARCINOMA PATIENTS
Liver cancer has been known to be the sixth cause of cancer worldwide. In Egypt, it is thefourth cause of cancer and the second -related mortality. The P53 is considered the guardian ofthe genome to prevent accumulation of oncogenic mutations that lead to malignant tumor.The study compared the circulating tumor DNA (ctDNA) by targeting hotspot mutation genelocus TP53 rs28934571 (c.747G>T) in normal persons, chronic liver disease patients, and inhepatocellular carcinoma (HCC) ones to evaluate its diagnostic value and analyses the ctDNAby targeting the hotspot mutation gene locus TP53 rs28934571 (c.747G>T).The results showed that of 100 adults, G1: Eighty (80%) patients were diagnosed as HCC ontop of HCV, ten (10%) as HCV patients and ten (10%) healthy controls. All groups were matchedas to age and sex. The AST was increased in HCC patients as compared to healthy control(P =0.018), forty patients (50%) were within Milan criteria, 12 patients (15%) withinUSCF, 28 (35%) were beyond all of whom 39 (48.75%) patients were child A with meanscore of 12.45±5.94. Forty (50%) patients had one focal lesion, 16 patients had two focal lesions,eight patients had four focal lesions and six patients had multiple lesions. The averagesize of lesion in cm was (5.58±3.66). Among the HCC patients 38 (47.5%) patients developedascites, 35 (43.75%) patients developed PVT and 9 (11.25%) patients developed encephalopathy.There was no significant difference in genetic typing between HCC patients, HCV onesand healthy controls (p =0.622).
- 1 August 2023
- Published by Egyptian Knowledge Bank in Journal of the Egyptian Society of Parasitology
- Vol. 53 (2) , 227-232
Open AccessEVALUATION OF CLINICAL UTILITY OF DETECTING CIRCULATING TUMOR DNA MUTATION GENE LOCUS TP53 RS28934571 USING REAL TIME PCR AND DROPLET DIGITAL PCR IN EGYPTIAN HEPATOCELLULAR CARCINOMA PATIENTS
Liver cancer has been known to be the sixth cause of cancer worldwide. In Egypt, it is thefourth cause of cancer and the second -related mortality. The P53 is considered the guardian ofthe genome to prevent accumulation of oncogenic mutations that lead to malignant tumor.The study compared the circulating tumor DNA (ctDNA) by targeting hotspot mutation genelocus TP53 rs28934571 (c.747G>T) in normal persons, chronic liver disease patients, and inhepatocellular carcinoma (HCC) ones to evaluate its diagnostic value and analyses the ctDNAby targeting the hotspot mutation gene locus TP53 rs28934571 (c.747G>T).The results showed that of 100 adults, G1: Eighty (80%) patients were diagnosed as HCC ontop of HCV, ten (10%) as HCV patients and ten (10%) healthy controls. All groups were matchedas to age and sex. The AST was increased in HCC patients as compared to healthy control(P =0.018), forty patients (50%) were within Milan criteria, 12 patients (15%) withinUSCF, 28 (35%) were beyond all of whom 39 (48.75%) patients were child A with meanscore of 12.45±5.94. Forty (50%) patients had one focal lesion, 16 patients had two focal lesions,eight patients had four focal lesions and six patients had multiple lesions. The averagesize of lesion in cm was (5.58±3.66). Among the HCC patients 38 (47.5%) patients developedascites, 35 (43.75%) patients developed PVT and 9 (11.25%) patients developed encephalopathy.There was no significant difference in genetic typing between HCC patients, HCV onesand healthy controls (p =0.622).
- Open Access
- 1 October 2021
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 114 (Supplement)
Complications of Hepatocellular Carcinoma patients post living Donor Liver Transplantation
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, accounting for about 1 million related deaths annually. An estimated 372, 000 new cases of hepatocellular carcinoma (HCC) are diagnosed each year, constituting 4.6% of all new human cancers. Objectives: The aim of our study was to study the complications of Hepatocellular Carcinoma patients post living Donor Liver Transplantation at Ain Shams Center for Organ Transplantation. Patients and methods: The study population underwent Living donor liver Transplanation due to hepatitis C virus related hepatocellular carcinoma during the period from January 2008 to 2019.A total number of 114 patients underwent LDLT due to HCV related hepatocellular carcinoma.Fourteen patients(12.2%) were excluded because of the intraoperative death or postoperative early death, 7 patients(6%) were excluded because of overlapping etiologies with hepatitis C (HBV,autoimmune hepatitis,BCS,…etc) and 11 patients (9.6%) were excluded due to their age.Eighty two patients fulfilling the inclusion criteria for enrollment were recruited in the study. Results: The most common complications were (45.1%) neuropsychiatric side effects induced by immunosuppressive treatment, malignancy, hypertension, renal impairment, stroke, small for size disease…etc. Biliary complications (34.1%) as well as sepsis (34.1%) were the second common complications then rejection (18.3%), recurrence (12.2%), death (11%) and vascular complications (10%). Conclusion: There was no statistical significance for those within or out side the Milan criteria or UCSF criteria and its impact on the occurrence of graft rejection, sepsis, vascular complications, death, HCC recurrence and biliary complications post-transplant.
- 1 October 2021
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 114 (Supplement)
Open AccessComplications of Hepatocellular Carcinoma patients post living Donor Liver Transplantation
Background: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, accounting for about 1 million related deaths annually. An estimated 372, 000 new cases of hepatocellular carcinoma (HCC) are diagnosed each year, constituting 4.6% of all new human cancers. Objectives: The aim of our study was to study the complications of Hepatocellular Carcinoma patients post living Donor Liver Transplantation at Ain Shams Center for Organ Transplantation. Patients and methods: The study population underwent Living donor liver Transplanation due to hepatitis C virus related hepatocellular carcinoma during the period from January 2008 to 2019.A total number of 114 patients underwent LDLT due to HCV related hepatocellular carcinoma.Fourteen patients(12.2%) were excluded because of the intraoperative death or postoperative early death, 7 patients(6%) were excluded because of overlapping etiologies with hepatitis C (HBV,autoimmune hepatitis,BCS,…etc) and 11 patients (9.6%) were excluded due to their age.Eighty two patients fulfilling the inclusion criteria for enrollment were recruited in the study. Results: The most common complications were (45.1%) neuropsychiatric side effects induced by immunosuppressive treatment, malignancy, hypertension, renal impairment, stroke, small for size disease…etc. Biliary complications (34.1%) as well as sepsis (34.1%) were the second common complications then rejection (18.3%), recurrence (12.2%), death (11%) and vascular complications (10%). Conclusion: There was no statistical significance for those within or out side the Milan criteria or UCSF criteria and its impact on the occurrence of graft rejection, sepsis, vascular complications, death, HCC recurrence and biliary complications post-transplant.
- 1 June 2020
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 21 (2) , 76-79
Effect of Ramadan fasting on Muslim recipients after living donor liver transplantation: A single center study
- 1 June 2020
- Published by Elsevier in Arab Journal of Gastroenterology
- Vol. 21 (2) , 76-79
Effect of Ramadan fasting on Muslim recipients after living donor liver transplantation: A single center study